Publications by authors named "D L P Baeten"
Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging.
Ther Adv Musculoskelet Dis
November 2024
Background: The efficacy and safety of bimekizumab (BKZ), an inhibitor of interleukin (IL)-17F in addition to IL-17A, has been established in axial spondyloarthritis (axSpA). Early assessment of new bone formation is possible using F-fluoride positron emission tomography-computerised tomography (PET-CT) imaging to quantitatively monitor osteoblastic activity.
Objectives: This exploratory study, initiated before phase IIb/III studies, assessed the efficacy and safety of BKZ in patients with radiographic (r-)axSpA and its effect on new bone formation.
Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.
J Allergy Clin Immunol
September 2023
Article Synopsis
- IL-17A is known to play a significant role in immune-mediated inflammatory diseases, while the function of IL-17F, which shares some similarity with IL-17A, is not well understood, though combining the inhibition of both shows potential benefits in treating psoriasis.
- In this study, researchers investigated how IL-17A and IL-17F are regulated in psoriatic disease using various advanced techniques, including RNA sequencing and a new cytokine-capture method.
- The findings highlight that IL-17F is expressed more than IL-17A in psoriatic conditions, with differing cell populations responsible for each isoform and their expression influenced by both inflammatory signals and medications, suggesting a need to target both IL-
Article Synopsis
- Spondyloarthritis (SpA) involves abnormal bone growth and inflammation, and current treatments mainly address inflammation but not bone growth; this study focuses on how specific blood vessels (type H) might play a role in SpA pathology.
- Researchers studied tmTNF-Tg mice, which mimic SpA features, and found increases in type H vessels and bone-forming cells before clinical symptoms appeared, indicating early changes in the disease.
- The findings suggest that type H vessels contribute to pathologic bone growth in SpA and highlight potential new treatment strategies targeting these vessels in the disease's progression.
The tumor necrosis factor (TNF) and IL-23/IL-17 axes are the main therapeutic targets in spondyloarthritis. Despite the clinical efficacy of blocking either pathway, monotherapy does not induce remission in all patients and its effect on new bone formation remains unclear. We aimed to study the effect of TNF and IL-17A dual inhibition on clinical disease and structural damage using the HLA-B27/human β2-microglobulin transgenic rat model of SpA.
View Article and Find Full Text PDFC-reactive protein (CRP) is an acute-phase protein in humans that is produced in high quantities by the liver upon infection and under inflammatory conditions. Although CRP is commonly used as a marker of inflammation, CRP can also directly contribute to inflammation by eliciting pro-inflammatory cytokine production by immune cells. Since CRP is highly elevated in serum under inflammatory conditions, we have studied the CRP-induced cytokine profile of human monocytes, one of the main innate immune cell populations in blood.
View Article and Find Full Text PDF